← All indications
Skin Neoplasms
Tumors or cancer of the SKIN.
Subtype terms (8)
More specific conditions that are subtypes of Skin Neoplasms in the MeSH hierarchy.
- Acanthoma
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Cutaneous Malignant Melanoma
- Mastocytosis, Cutaneous
4 drugs (3 approved, 1 experimental)
- Melanoma
1301 drugs (311 approved, 990 experimental)
- Non-Melanoma Skin Neoplasms
- Sebaceous Gland Neoplasms
- Sweat Gland Neoplasms
Drugs by status
Approved for this indication (4)
Phase 4 trials (11)
Phase 3 trials (17)
Phase 2 trials (87)
- 4-1bb selected til
- methylprednisolone
- pegylated arginine deiminase
- afatinib
- axitinib
- tazarotene
- alvac mart-1 vaccine
- anti-gp 100:154 tcell receptor peripheral blood lymphocyte
- anti-mart-1 f5 tcr pbl
- atezolizumab
- apx005m
- petrolatum, white
- Gusacitinib
- autologous anti-gp 100:154-162 t-cell receptor gene-engineered peripheral blood lymphocytes
- autologous anti-gp 100:154-162 t-cell receptor gene-engineered tumor infiltrating lymphocytes
- autologous anti-mart-1 f5 t-cell receptor
- autologous anti-mart-1 f5 t-cell receptor gene-engineered tumor infiltrating lymphocytes
- mk-1775
- azd-4547
- binimetinib
- cd8 enriched young til
- dabrafenib
- prednisone
- eflornithine
- vismodegib
- imatinib
- gp-100 peptide vaccine
- trametinib
- gsk-2636771
- ifx-1
- +57 more
Phase 1 trials (27)
- 131i-tenatumomab
- vitamin d3
- brodalumab
- cobimetinib
- fimaporfin
- bleomycin
- methyl aminolevulinate
- neo-pv-01
- vitamin c
- panobinostat
- polypodium leucotomos
- lidocaine
- methylene blue
- epinephrine
- vemurafenib
- urelumab
- xl888
- inactivated influenza vaccine
- sodium chloride
- vitamin a
- fludeoxyglucose f-18
- tozuleristide
- 2141 v-11
- veldoreotide
- dk210
- mq719
- onm-501
Organizations
Organization Involved with Phase 4 Indications (15)
- AboutSkin Dermatology and DermSurgery, PC
- Medicis
- Amgen
- Pfizer
- Wyeth
- Case Western Reserve University
- Sichuan University
- University Hospital of Berlin
- University of Zurich
- University of California, San Francisco
- University of Alabama, Birmingham
- Humboldt University
- Department of Veteran Affairs
- People's Liberation Army of China
- Chinese Academy of Medical Sciences
Organization Involved with Phase 3 Indications (18)
- Bristol-Myers Squibb
- Provectus Biopharmaceuticals, Inc.
- National Cancer Institute (NCI)
- ECOG-ACRIN Cancer Research Group
- Emory University
- Indiana University
- Katholieke Universiteit Leuven
- Southwest Oncology Group
- Tufts University
- University of Nottingham
- University of Sydney
- St. Luke's University Health Network, Bethlehem, PA
- University of Lyon
- University of Texas at Houston
- University of Wisconsin
- Trans Tasman Radiation Oncology Group
- The Royal Australian and New Zealand College of Radiologists
- Johnson and Johnson
Organization Involved with Phase 2 Indications (94)
- Incyte
- AbbVie
- DFB Pharma
- DUSA Pharmaceuticals
- Celgene
- OSI Pharmaceuticals
- Roche
- Schering-Plough
- AstraZeneca
- Merck
- Merck Serono
- Exelixis
- Genentech
- Merck KGaA
- Novartis
- Stamford Pharmaceuticals
- Catalysis SL
- Cosmo Pharmaceuticals
- GlaxoSmithKline
- Oncovir, Inc.
- Oncology Venture
- Philogen S.p.A.
- Sponsor GmbH
- Vical
- Healthpoint
- Point Therapeutics
- National Institutes of Health (NIH)
- British Columbia Cancer Agency
- National Cancer Institute, France
- University of Arizona
- +64 more
Organization Involved with Phase 1 Indications (28)
- Blaze Bioscience Inc.
- CureVac AG
- Incuron
- Leadiant Biosciences, Inc.
- PCI Biotech AS
- Vaccinex Inc.
- Fondazione Giovanni Pascale
- United States Navy
- Rockefeller University
- University of London
- Johns Hopkins University
- Providence Health & Services
- University of Rochester
- Yale University
- Neon Therapeutics
- Medpace, Inc.
- Al Azhar University
- Methodist Cancer Center, Houston, Texas
- University of Massachusetts
- State of Texas
- James B. and Lois R. Archer Charitable Foundation
- Gateway for Cancer Research
- Yeshiva University
- Xynomic Pharmaceuticals, Inc.
- Morphogenesis, Inc.
- Iovance
- Qassim University
- ImmVira Pharma Co. Ltd
Organization Involved with Other Experimental Indications (23)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Dartmouth University
- John Wayne Cancer Institute
- Norwegian University of Science and Technology
- Osaka University
- University of Manchester
- University of Maryland
- University of Bergen
- West Virginia University
- Columbia University
- University of Chicago
- University of Campinas
- International Center for Diarrheal Disease Research
- Delcath Systems
- Sky Ridge Medical Center
- Morristown Memorial Hospital
- University of Nice Sophia Antipolis
- Hudlegekontoret Lillehammer
- University of Bradford
- V Foundation
- University of Stavanger
- Ghent University
- Oslo Metropolitan University